A Phase 1 study of ONC-841 in advanced solid tumors

Study Description

A clinical trial testing a new antibody drug called ONC-841 in patients with advanced solid tumors

Study Details

Registry ID:

NCT06352359

Conditions:

Advanced Solid Tumor

Phase:

Phase 1

Target Enrollment:

72 participants

Start Date:

August 23, 2024

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (9 sites)

• Thomas Jefferson University Hospital
  Philadelphia, PennsylvaniaUnited States, United States
• AdventHealth Medical Group Oncology Research at Celebration
  Kissimmee, FloridaUnited States, United States
• UF Health Cancer Center, University of Florida
  Gainesville, FloridaUnited States, United States
• Rogel Cancer Center, University of Michigan
  Ann Arbor, MichiganUnited States, United States
• Norton Cancer Center
  Louisville, KentuckyUnited States, United States
• Tranquil Clinical Research
  Houston, TexasUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• Huntsman Cancer Institute, University of Utah
  Salt Lake City, UtahUnited States, United States
• University of California at Davis Cancer Center
  Sacramento, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →